Cosmos HoldingsCOSM
COSM
About: Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Employees: 149
0
Funds holding %
of 7,428 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 18 [Q1] → 18 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
8.21% less ownership
Funds ownership: 11.69% [Q1] → 3.49% (-8.21%) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
64% less capital invested
Capital invested by funds: $1.19M [Q1] → $421K (-$765K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for COSM.
Financial journalist opinion
Based on 3 articles about COSM published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025
CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025 Income Statement Cosmos Health continued its positive trajectory in Q2 2025, delivering double-digit revenue growth of 11.66% and a 51.60% increase in gross profit.
Neutral
GlobeNewsWire
1 week ago
Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy
CHICAGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, announced today that it has commenced purchases of Ethereum (ETH), advancing its digital asset treasury reserve strategy. Pursuant to its financing facility of up to $300 million (the “Facility”) with a U.S.-based institutional investor, Cosmos Health has completed its initial $1 million purchase of ETH.
Neutral
GlobeNewsWire
2 weeks ago
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy
Cosmos Health secures financing of up to $300 million to develop an ETH-backed treasury, with remaining proceeds for growth and general working capital
Neutral
GlobeNewsWire
2 months ago
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC (“DolCas”), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients. Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company's operational expansion.
Neutral
GlobeNewsWire
3 months ago
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance.
Neutral
GlobeNewsWire
3 months ago
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance.
Neutral
GlobeNewsWire
3 months ago
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Company's objective of surpassing 3 million units in cumulative orders over the first five years.
Neutral
GlobeNewsWire
3 months ago
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was notified by Nasdaq that it was not in compliance with the $1.00 minimum bid price requirement, as the closing bid price of the Company's common stock had remained below $1.00 for 30 consecutive business days.
Neutral
GlobeNewsWire
3 months ago
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr.
Neutral
GlobeNewsWire
4 months ago
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year.
Charts implemented using Lightweight Charts™